Verve Therapeutics Inc.
13F holders, Q2 2026 (June 30)2holders −1
1new positions
1sold out
$0.00avg. 13F price*
At the end of Q2 2026, 2 institutions reported holding Verve Therapeutics Inc. in their 13F filings, down 1 from Q1 2026. 1 opened new positions and 1 sold out. The largest holders were Financial Gravity Companies, Inc. ($0) and GAMMA Investing LLC ($0).
- Company
- Verve Therapeutics Inc.
- CUSIP
- 925CVR011
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $0 |
| Exits | 1 | $0 |
All 13F filers, Q1 2026 → Q2 2026: 257 shares bought and 43 shares sold, net +214 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Financial Gravity Companies, Inc. | 0.00% | — | 1 | $0 |
| GAMMA Investing LLC | 0.00% | New | 257 | $0 |
"% of holder's portfolio" is VERVE THERAPEUTICS INC's weight in each manager's 13F, not the share of Verve Therapeutics Inc. the manager owns.